Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind single-center study of a 15-valent pneumococcal conjugate vaccine in infants and children
CTR20231016Phase 3Active
- Sponsor
- Zhifei Green Bamboo
- Start
- Jul 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of 15-valent pneumococcal conjugate vaccine in pneumococcal disease (5 arms), sponsored by Zhifei Green Bamboo. Primary endpoints: Serotype-specific pneumococcal IgG geometric mean concentration and Proportion with serotype-specific IgG concentration >=0.35 μg/mL. Started Jul 2023; status: active.
02
Drugs
15-valent pneumococcal conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on CTR20231016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231016.